| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6126920 | MYLAN | Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition |
Mar, 2016
(8 years ago) | |
| US7078058 | MYLAN | Corticosteroid-containing pharmaceutical composition |
May, 2017
(6 years ago) | |
Luxiq is owned by Mylan.
Luxiq contains Betamethasone Valerate.
Luxiq has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Luxiq are:
- US6126920
- US7078058
Luxiq was authorised for market use on 28 February, 1999.
Luxiq is available in aerosol, foam;topical dosage forms.
Luxiq can be used as method of treating a skin disease with a corticosteroid-containing pharmaceutical composition.
The generics of Luxiq are possible to be released after 24 May, 2017.
Drugs and Companies using BETAMETHASONE VALERATE ingredient
Market Authorisation Date: 28 February, 1999
Treatment: Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition
Dosage: AEROSOL, FOAM;TOPICAL
How can I launch a generic of LUXIQ before it's drug patent expiration?
More Information on Dosage
LUXIQ family patents
